RWS (RWS) PT Raised to GBX 615 at Berenberg Bank

Share on StockTwits

RWS (LON:RWS) had its price objective increased by equities research analysts at Berenberg Bank from GBX 530 ($6.93) to GBX 615 ($8.04) in a report released on Thursday, ThisIsMoney.Co.Uk reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 8.47% from the company’s previous close.

Separately, Barclays assumed coverage on RWS in a research note on Friday, January 18th. They issued an “overweight” rating and a GBX 560 ($7.32) price objective on the stock.

LON:RWS opened at GBX 567 ($7.41) on Thursday. The company has a debt-to-equity ratio of 29.07, a quick ratio of 1.32 and a current ratio of 1.46. The company has a market capitalization of $1.55 billion and a price-to-earnings ratio of 54.52. RWS has a 12-month low of GBX 335.50 ($4.38) and a 12-month high of GBX 536.28 ($7.01).

About RWS

RWS Holdings plc engages in the translation, intellectual property (IP) support, life sciences language, and localization businesses. The company operates through four segments: Patent Translation & Filing, Patent Information, Life Sciences, and Language Solutions. The Patent Translation & Filing segment undertakes patent translation and filing services of patent activities, as well as IP translations for litigation and information purposes, including prior-art documents, office actions, opposition proceedings and correspondence, and written opinions of international searching authorities.

Featured Story: Stop Order Uses For Individual Investors

Receive News & Ratings for RWS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RWS and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Two Rivers Bancorp  Given Average Rating of “Strong Buy” by Analysts
Two Rivers Bancorp Given Average Rating of “Strong Buy” by Analysts
Cowen Begins Coverage on CarGurus
Cowen Begins Coverage on CarGurus
Contrasting Verb Technology  and UniFirst
Contrasting Verb Technology and UniFirst
Abbott Laboratories  Upgraded to Buy at Zacks Investment Research
Abbott Laboratories Upgraded to Buy at Zacks Investment Research
LeMaitre Vascular  Rating Lowered to Sell at BidaskClub
LeMaitre Vascular Rating Lowered to Sell at BidaskClub
Kimball Electronics  Stock Rating Upgraded by BidaskClub
Kimball Electronics Stock Rating Upgraded by BidaskClub


© 2006-2019 Ticker Report